Metabolism News and Research

Latest Metabolism News and Research

High plasma selenium concentrations linked to lower occurrence of dysglycemia in elderly men

The role of selenium in diabetes has been controversial, with some studies suggesting that it raises diabetes risk and others finding that it is protective. Now, research published in BioMed Central's open access journal Nutrition and Metabolism, has shown that, for men, high plasma selenium concentrations are associated with a lower occurrence of dysglycemia.

18 Mar 2010

PAREXEL genotypes over 10,000 potential study participants to identify 400 CYP2D6 poor metabolizers

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has completed a large and complex pharmacogenetics-based early phase study. The study was conducted in a healthy volunteer population of poor metabolizers of Cytochrome P450 2D6 (CYP2D6), an important enzyme involved in the metabolism of drugs. The study monitored the QTc interval following administration of a neurological treatment, which has been shown to have a higher drug exposure in poor metabolizers of CYP2D6.

From Parexel 17 Mar 2010

Low-impact, weight-bearing exercise does not affect bone density during weight loss

While there are many benefits of losing weight, weight reduction also might negatively affect bones in the body. During weight loss, bones are being remodeled - breaking down old bone and forming new bone - at an accelerated rate.

17 Mar 2010

Pathway Genomics' personal Genetic Health Report now available

Pathway Genomics Inc., a U.S. based genetic testing company, announced the immediate availability of its personal Genetic Health Report. This customized and innovative personal genetic health report contains information on more than 70 health conditions, including pharmacogenetics (prescription medication response), propensity for complex disease, and carrier status (pre-pregnancy health).

17 Mar 2010

Anti-obesity drugs fail to tackle wider issues of obesity

Scientists at the University of Liverpool argue that anti-obesity drugs fail to provide lasting benefits for health and wellbeing because they tackle the biological consequences of obesity, and not the important psychological causes of overconsumption and weight gain.

17 Mar 2010

Obesity and passive smoking are risk factors for elevated umbilical cord neonatal immature

Babies born to mothers with obesity and exposed to passive smoking are more likely to have health problems than others. This conclusion is based on evidence of elevated levels of nucleated red blood cells in the umbilical cord reported in the International Journal of Food Safety, Nutrition and Public Health.

17 Mar 2010

Lantheus Medical Imaging announces preliminary data on flurpiridaz F 18 PET MPI agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced preliminary data on flurpiridaz F 18 (formerly known as BMS747158), its novel compound in development as a Positron Emission Tomography (PET) myocardial perfusion imaging (MPI) agent. The study of nine patients compared rest-stress flurpiridaz F 18 PET MPI, with rest-stress technetium-99m (Tc-99m) labeled single photon emission computed tomography (SPECT) for the detection and evaluation of coronary artery disease (CAD).

16 Mar 2010

Vitamin D supplements might do more harm than good for African-American patients

Vitamin D is quickly becoming the "go-to" remedy for treating a wide range of illnesses, from osteoporosis to atherosclerosis. However, new evidence from a Wake Forest University School of Medicine study suggests that supplementing vitamin D in those with low levels may have different effects based on patient race and, in black individuals, the supplement could actually do harm.

16 Mar 2010

Roche Diagnostics named sole source supplier for Premier's blood glucose monitoring devices

Roche Diagnostics announced today that it has been awarded contracts for blood glucose monitoring and clinical chemistry/immunoassay lab analyzers from Premier Purchasing Partners, L.P., Inc., the group purchasing unit of Premier, Inc. Roche was also named the sole source supplier for blood glucose in Premier's exclusive ASCEND supply chain performance program.

From Roche Sequencing and Life Science 16 Mar 2010

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that data from a phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were published in The Lancet. This study met its primary endpoint, resulting in an average LDL-C reduction of greater than 100 mg/dL in this very high-risk patient population.

16 Mar 2010

Mother's obesity can significantly increase offspring’s susceptibility to obesity

Aspiring moms may be advised to achieve a healthy weight before they become pregnant, and to gain only the recommended amount of weight during their pregnancy

16 Mar 2010

Comparison study of genetic tests for ASD finds CMA with highest detection rate

The Autism Consortium, an innovative research, clinical and family collaboration dedicated to catalyzing research and enhancing clinical care for families with autism spectrum disorders (ASDs), announced today that the results of its comparison study of genetic testing methods for autism spectrum disorders is available from the journal Pediatrics through early online release in their eFirst pages today and will appear in the journal's April issue.

15 Mar 2010

Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new pre-clinical data from its hypercholesterolemia program, performed in collaboration with scientists at the University of Texas Southwestern Medical Center at Dallas. The data were presented at the PCSK9 Conference: From Gene to Therapeutics held in Nantes, France from March 11-13, 2010.

15 Mar 2010

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.

15 Mar 2010

NDA for BYDUREON: FDA issues complete response letter

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for BYDUREON™ (exenatide for extended-release injectable suspension).

15 Mar 2010

Supplementing vitamin D in people with low levels may have different effects based on patient race

15 Mar 2010

Nanoparticles provide a targeted version of photothermal therapy for cancer

In a lecture he delivered in 1906, the German physician Paul Ehrlich coined the term Zuberkugel, or "magic bullet," as shorthand for a highly targeted medical treatment.

15 Mar 2010

New study finds green tea extract may prevent Alzheimer's disease and dementia

Long known to be beneficial in heart disease, diabetes and some cancers, a new study finds a specific green tea extract may delay or prevent Alzheimer's disease and dementia. A. Holliday & Company's "Teawell 50," is a 50 percent pure extraction of EGCG (epigallocatechin gallate) – a flavonoid which is the most potent of four major catechins in green tea.

15 Mar 2010

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate).

12 Mar 2010

$ASBMR Task Force studies link between long-term bisphosphonate usage and rare bone fractures$

ASBMR Task Force studies link between long-term bisphosphonate usage and rare bone fractures

Recent reports suggesting a link between long-term bisphosphonate usage and rare bone fractures have sparked rising concern among patients, health care professionals and the public. The American Society of Bone and Mineral Research (ASBMR) is examining this urgent clinical issue and will present its findings later this year.

12 Mar 2010

Metabolism News and Research

Latest Metabolism News and Research

High plasma selenium concentrations linked to lower occurrence of dysglycemia in elderly men

PAREXEL genotypes over 10,000 potential study participants to identify 400 CYP2D6 poor metabolizers

Low-impact, weight-bearing exercise does not affect bone density during weight loss

Pathway Genomics' personal Genetic Health Report now available

Anti-obesity drugs fail to tackle wider issues of obesity

Obesity and passive smoking are risk factors for elevated umbilical cord neonatal immature

Lantheus Medical Imaging announces preliminary data on flurpiridaz F 18 PET MPI agent

Vitamin D supplements might do more harm than good for African-American patients

Roche Diagnostics named sole source supplier for Premier's blood glucose monitoring devices

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Mother's obesity can significantly increase offspring’s susceptibility to obesity

Comparison study of genetic tests for ASD finds CMA with highest detection rate

Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

NDA for BYDUREON: FDA issues complete response letter

Supplementing vitamin D in people with low levels may have different effects based on patient race

Nanoparticles provide a targeted version of photothermal therapy for cancer

New study finds green tea extract may prevent Alzheimer's disease and dementia

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

ASBMR Task Force studies link between long-term bisphosphonate usage and rare bone fractures

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves